Glucotrack, Inc. (NASDAQ: GCTK)

Glucotrack, Inc. is a medical device company focused on the development of an implantable continuous blood glucose monitor for individuals with Type 1 diabetes and Type 2 diabetes who use insulin or are at risk for hypoglycemia. The company previously marketed a non invasive glucose sensor that clipped onto the earlobe but shifted its efforts in 2023 to the implantable approach after obtaining feedback from early trials. The implantable sensor is designed to reside in a blood vessel to provide real time glucose measurements without the lag seen in interstitial fluid based systems. Glucotrack aims to deliver a device that can function for multiple years after a single implantation procedure. The company has completed multiple preclinical animal studies demonstrating sensor functionality and safety up to six months. It also completed a first in human study in 2025 that showed no serious safety events and performance consistent with earlier animal data. Glucotrack has obtained ISO 13485 certification and has filed three U. S. patents covering sensor design, power consumption and signal stability.

Glucotrack, Inc. has not yet commenced commercial sales of its product and therefore does not generate revenue from product sales. The company is currently financed through private placements and may seek additional funding through partnerships or licensing agreements once regulatory milestones are reached. No specific revenue streams are disclosed in the filing.

The glucose monitoring market is dominated by a few large companies that offer transcutaneous continuous glucose monitors with sensor lives ranging from seven to fifteen days. Abbott Laboratories, DexCom, and Medtronic together account for the majority of worldwide sales while Senseonics Holdings provides the only commercially available implantable sensor that lasts up to one year. Glucotrack, Inc. differentiates itself by proposing a fully implantable system that measures glucose directly in blood thereby eliminating the lag associated with interstitial fluid measurements and by targeting a sensor life of multiple years. The company also highlights potential advantages in accuracy, durability, and discretion which could appeal to patients and providers seeking a less intrusive long term solution. In addition Glucotrack notes that its intravascular approach may reduce the risk of foreign body reaction compared with subcutaneous sensors and could enable integration with other therapies such as spinal cord stimulation.

The company intends to serve individuals with Type 1 diabetes and insulin requiring Type 2 diabetes who need frequent glucose monitoring to manage their condition. According to the International Diabetes Federation approximately 589 million adults worldwide had diabetes in 2025 representing about ten percent of the global adult population. In the United States the Centers for Disease Control and Prevention estimated 40.1 million people had diabetes in 2021. Potential customers also include hospitals, clinics, and health insurers that may cover the device and its implantation procedure. No specific customer names are mentioned in the filing.